The global optical preclinical imaging market size was valued at USD 640.4 million in 2023, driven by rising technical advancements in optical imaging facilitating smooth drug development across the globe. The market is expected to grow at a CAGR of 5% during the forecast period of 2024-2032, with the values likely to rise from USD 672.4 million in 2024 to USD 992.5 million by 2032.
Preclinical imaging is an essential diagnostic and research tool used in drug development and discovery. Preclinical imaging includes micro-ultrasound, optical imaging, CT, PET, and MRIs, among others. Optical imaging is divided into bioluminescence and fluorescence. It is rapid, easy to perform, and is commonly used for molecular visualizations. It can prove to be highly effective for the pharmaceutical industry as it enables the prior analysis of drugs in pipeline, facilitating faster drug development.
The sudden outbreak of COVID-19 and increasing prevalence of chronic diseases has expediated drug and vaccine development. With the ongoing trend of machine learning and artificial intelligence, the healthcare industry is witnessing the convergence of new technologies into medical ecosystem. This is has led to significant optical preclinical imaging market demand.
Animals are often used as the initial model for testing and determining the effects of a drug. However, collecting the data sets can be difficult, owing to their different sizes and physical positions. To solve this problem, InVivo analytics has developed a fast cloud-based data analysis platform called InVIvoAX. Imaging software like Harmony® and Columbus™ are being used for high content imaging, data storage and analysis.
The optical preclinical imaging market growth can also be accredited to the advent of new imaging technologies. Researchers have introduced imaging mass cytometry to analyze the detection of proteins within tissue sections with the help of heavy metal tagged antibodies. In September 2023, Revvity Inc., unveiled an enhanced imaging portfolio in preclinical research which includes IVIS® Spectrum 2 and the IVIS SpectrumCT 2 imaging systems, crafted to elevate the sensitivity standards in in vivo optical imaging.
To facilitate fast-tracking and rapid evaluation of therapeutic candidates, Revvity's QuantumTM GX3 microCT structural imaging solution has been enabled with increased resolution and speed for both in vivo and ex vivo imaging. Such product launches will add significant growth the optical preclinical imaging market value.
Market Breakup by Modality
Market Breakup by Reagent
Market Breakup by Application
Market Breakup by End User
Market Breakup by Region
The United States is expected to lead the optical preclinical imaging market share with the implementation of the Inflation Reduction Act of 2022. This act emphasizes the reduction of device and drug prices in the country. This indicates that the traditional research and development methods will take a backseat as the pharma companies keenly adopt machine learning and artificial intelligence technology driven platforms to accelerate drug development. The integration has already been initiated and it is fairly smooth, owing to the presence of a robust healthcare infrastructure.
Europe has been one of the leading regions in the market as it is home to several academic institutions, pioneering research and development in numerous healthcare domains. Asia Pacific is also expected to witness the fastest growth attributed to rising medical infrastructure development. In addition, major healthcare companies have been making hefty investments in the region to leverage the easy availability of both economical and intellectual resources.
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
|Scope of the Report||
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|Breakup by Modality||
|Breakup by Reagent||
|Breakup by Application||
|Breakup by End User||
|Breakup by Region||
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Optical Preclinical Imaging Market Overview
3.1 Global Optical Preclinical Imaging Market Historical Value (2017-2023)
3.2 Global Optical Preclinical Imaging Market Forecast Value (2024-2032)
4 Global Optical Preclinical Imaging Market Landscape
4.1 Global Optical Preclinical Imaging Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Optical Preclinical Imaging Product Landscape
4.2.1 Analysis by Modality
4.2.2 Analysis by Reagent
4.2.3 Analysis by Application
5 Global Optical Preclinical Imaging Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Optical Preclinical Imaging Market Segmentation
6.1 Global Optical Preclinical Imaging Market by Modality
6.1.1 Market Overview
6.1.2 Bioluminescence/Fluorescence Imaging Systems
6.1.3 Standalone Fluorescence Imaging Systems
6.1.4 Optical + X-Ray/ Optical + CT
6.2 Global Optical Preclinical Imaging Market by Reagent
6.2.1 Market Overview
6.2.2 Bioluminescent Imaging Reagents
6.2.3 Fluorescent Imaging Reagent
6.3 Global Optical Preclinical Imaging Market by Application
6.3.1 Market Overview
6.3.2 Research and Development
6.3.3 Drug Discovery
6.4 Global Optical Preclinical Imaging Market by End User
6.4.1 Market Overview
6.4.2 Pharma and Biotech Companies
6.4.3 Research Institutes
6.5 Global Optical Preclinical Imaging Market by Region
6.5.1 Market Overview
6.5.2 North America
6.5.4 Asia Pacific
6.5.5 Latin America
6.5.6 Middle East and Africa
7 North America Optical Preclinical Imaging Market
7.1 Market Share by Country
7.2 United States of America
8 Europe Optical Preclinical Imaging Market
8.1 Market Share by Country
8.2 United Kingdom
9 Asia Pacific Optical Preclinical Imaging Market
9.1 Market Share by Country
10 Latin America Optical Preclinical Imaging Market
10.1 Market Share by Country
11 Middle East and Africa Optical Preclinical Imaging Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.5 South Africa
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding & Investment Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Supplier Landscape
16.1.1 Financial Analysis
16.1.2 Product Portfolio
16.1.3 Demographic Reach and Achievements
16.1.4 Mergers and Acquisitions
16.2.1 Financial Analysis
16.2.2 Product Portfolio
16.2.3 Demographic Reach and Achievements
16.2.4 Mergers and Acquisitions
16.3 NuVasive Inc.
16.3.1 Financial Analysis
16.3.2 Product Portfolio
16.3.3 Demographic Reach and Achievements
16.3.4 Mergers and Acquisitions
16.4 Arthrex Inc.
16.4.1 Financial Analysis
16.4.2 Financial Portfolio
16.4.3 Demographic Reach and Achievements
16.4.4 Mergers and Acquisitions
16.5 Orthofix US LLC
16.5.1 Financial Analysis
16.5.2 Product Portfolio
16.5.3 Demographic Reach and Achievements
16.5.4 Mergers and Acquisitions
16.6 Johnson & Johnson Services, Inc.
16.6.1 Financial Analysis
16.6.2 Product Portfolio
16.6.3 Demographic Reach and Achievements
16.6.4 Mergers and Acquisitions
16.7 Pega Medical Inc.
16.7.1 Financial Analysis
16.7.2 Product Portfolio
16.7.3 Demographic Reach and Achievements
16.7.4 Mergers and Acquisitions
16.8 WishBone Medical
16.8.1 Financial Analysis
16.8.2 Product Portfolio
16.8.3 Demographic Reach and Achievements
16.8.4 Mergers and Acquisitions
16.9 Zimmer Biomet
16.9.1 Financial Analysis
16.9.2 Product Portfolio
16.9.3 Demographic Reach and Achievements
16.9.4 Mergers and Acquisitions
16.10.1 Financial Analysis
16.10.2 Product Portfolio
16.10.3 Demographic Reach and Achievements
16.10.4 Mergers and Acquisitions
16.11 Auxein Medical
16.11.1 Financial Analysis
16.11.2 Product Portfolio
16.11.3 Demographic Reach and Achievements
16.11.4 Mergers and Acquisitions
16.12 Implanet SA
16.12.1 Financial Analysis
16.12.2 Product Portfolio
16.12.3 Demographic Reach and Achievements
16.12.4 Mergers and Acquisitions
16.13 Merete GmbH
16.13.1 Financial Analysis
16.13.2 Product Portfolio
16.13.3 Demographic Reach and Achievements
16.13.4 Mergers and Acquisitions
16.14 Mighty Oak Medical
16.14.1 Financial Analysis
16.14.2 Product Portfolio
16.14.3 Demographic Reach and Achievements
16.14.4 Mergers and Acquisitions
17 Global Optical Preclinical Imaging Market - Distribution Model (Additional Insight)
17.2 Potential Distributors
17.3 Key Parameters for Distribution Partner Assessment
18 Key Opinion Leaders (KOL) Insights (Additional Insight)
19 Company Competitiveness Analysis (Additional Insight)
19.1 Very Small Companies
19.2 Small Companies
19.3 Mid-Sized Companies
19.4 Large Companies
19.5 Very Large Companies
20 Payment Methods (Additional Insight)
20.1 Government Funded
20.2 Private Insurance
*Additional insights provided are customisable as per client requirements.
The market attained a value of about USD 640.4 million in 2023, driven by the increasing prevalence of chronic diseases across the globe.
The market is anticipated to grow at a CAGR of 5% during the forecast period of 2024-2032, likely to reach a market value of USD 992.5 million by 2032.
The key drivers include ongoing trend of machine learning and artificial intelligence, the healthcare industry.
Artificial intelligence and machine learning integration in the pharmaceutical industry is the current market trend. InVivo analytics has launched a cloud-based data analysis platform called InVIvoAX. Harmony® and Columbus™ are software used for high content imaging, data storage and analysis.
Common application areas include research and development and drug discovery.
Bioluminescent imaging reagents and fluorescent imaging reagents are commonly used.
It includes Bioluminescence/Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray/ Optical + CT.
Major end users include research institutes, pharma and biotech companies, among others.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America is currently leading the global market.
Key players involved in the market are Stryker, Smith+Nephew, NuVasive Inc., Arthrex Inc., Orthofix US LLC, Johnson & Johnson Services, Inc., Pega Medical Inc., WishBone Medical, Zimmer Biomet, Medtronic, Auxein Medical, Implanet SA, Merete GmbH, and Mighty Oak Medical.
Single User License
Five User License
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.